GU Cancers 2025 | The future of gut microbiome modulation in managing urothelial carcinoma
Soufyan Annakib
• 14 Feb 2025
Soufyan Annakib, MD, Centre Hospitalier Universitaire de Nîmes, Nîmes, France, comments on the emerging role fecal transplantation or germ supplementation to modulate the patient’s microbiome and improve the efficacy of immune checkpoint inhibitors such as pembrolizumab. RNA-Seq can also be further utilized to analyze stool samples of patients before treatment to identify potential biomarkers or signatures associated with treatment response. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
